FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901802145> ?p ?o ?g. }

• W2901802145 abstract "Reprogrammed energy metabolism has become an emerging hallmark of cancer in recent years. Transporters have been reported to be amino acid sensors involved in controlling mTOR recruitment and activation, which is crucial for the growth of both normal and tumor cells. L-type amino acid transporter 2 (LAT2), encoded by the SLC7A8 gene, is a Na+-independent neutral amino acid transporter and is responsible for transporting neutral amino acids, including glutamine, which can activate mTOR. Previous studies have shown that LAT2 was overexpressed in gemcitabine-resistant pancreatic cancer cells. However, the role of LAT2 in chemoresistance in pancreatic cancer remains uncertain and elusive.The effects of LAT2 on biological behaviors were analyzed. LAT2 and LDHB levels in tissues were detected, and the clinical value was evaluated.We demonstrated that LAT2 emerged as an oncogenic protein and could decrease the gemcitabine sensitivity of pancreatic cancer cells in vitro and in vivo. The results of a survival analysis indicated that high expression levels of both LAT2 and LDHB predicted a poor prognosis in patients with pancreatic cancer. Furthermore, we found that LAT2 could promote proliferation, inhibit apoptosis, activate glycolysis and alter glutamine metabolism to activate mTOR in vitro and in vivo. Next, we found that gemcitabine combined with an mTOR inhibitor (RAD001) could reverse the decrease in chemosensitivity caused by LAT2 overexpression in pancreatic cancer cells. Mechanistically, we demonstrated that LAT2 could regulate two glutamine-dependent positive feedback loops (the LAT2/p-mTORSer2448 loop and the glutamine/p-mTORSer2448/glutamine synthetase loop) to promote glycolysis and decrease gemcitabine (GEM) sensitivity in pancreatic cancer.Taken together, our data reveal that LAT2 functions as an oncogenic protein and could regulate glutamine-dependent mTOR activation to promote glycolysis and decrease GEM sensitivity in pancreatic cancer. The LAT2-mTOR-LDHB pathway might be a promising therapeutic target in pancreatic cancer." @default.
• W2901802145 created "2018-11-29" @default.
• W2901802145 creator A5000993585 @default.
• W2901802145 creator A5004208059 @default.
• W2901802145 creator A5024958140 @default.
• W2901802145 creator A5028351634 @default.
• W2901802145 creator A5039153796 @default.
• W2901802145 creator A5044239966 @default.
• W2901802145 creator A5048501863 @default.
• W2901802145 creator A5064813580 @default.
• W2901802145 creator A5070412209 @default.
• W2901802145 creator A5091539607 @default.
• W2901802145 date "2018-11-12" @default.
• W2901802145 modified "2023-10-16" @default.
• W2901802145 title "LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer" @default.
• W2901802145 cites W1493801922 @default.
• W2901802145 cites W1993858744 @default.
• W2901802145 cites W2003997444 @default.
• W2901802145 cites W2011356964 @default.
• W2901802145 cites W2014988241 @default.
• W2901802145 cites W2023253424 @default.
• W2901802145 cites W2039979943 @default.
• W2901802145 cites W2055255976 @default.
• W2901802145 cites W2117692326 @default.
• W2901802145 cites W2141517721 @default.
• W2901802145 cites W2157760261 @default.
• W2901802145 cites W2182249053 @default.
• W2901802145 cites W2207814108 @default.
• W2901802145 cites W2321688623 @default.
• W2901802145 cites W2343650972 @default.
• W2901802145 cites W2395401987 @default.
• W2901802145 cites W2401384141 @default.
• W2901802145 cites W2519232588 @default.
• W2901802145 cites W2531263810 @default.
• W2901802145 cites W2534904302 @default.
• W2901802145 cites W2535462468 @default.
• W2901802145 cites W2568414132 @default.
• W2901802145 cites W2589582915 @default.
• W2901802145 cites W2598266532 @default.
• W2901802145 cites W2781525129 @default.
• W2901802145 cites W2787553551 @default.
• W2901802145 cites W2789417385 @default.
• W2901802145 doi "https://doi.org/10.1186/s13046-018-0947-4" @default.
• W2901802145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6233565" @default.
• W2901802145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30419950" @default.
• W2901802145 hasPublicationYear "2018" @default.
• W2901802145 type Work @default.
• W2901802145 sameAs 2901802145 @default.
• W2901802145 citedByCount "76" @default.
• W2901802145 countsByYear W29018021452019 @default.
• W2901802145 countsByYear W29018021452020 @default.
• W2901802145 countsByYear W29018021452021 @default.
• W2901802145 countsByYear W29018021452022 @default.
• W2901802145 countsByYear W29018021452023 @default.
• W2901802145 crossrefType "journal-article" @default.
• W2901802145 hasAuthorship W2901802145A5000993585 @default.
• W2901802145 hasAuthorship W2901802145A5004208059 @default.
• W2901802145 hasAuthorship W2901802145A5024958140 @default.
• W2901802145 hasAuthorship W2901802145A5028351634 @default.
• W2901802145 hasAuthorship W2901802145A5039153796 @default.
• W2901802145 hasAuthorship W2901802145A5044239966 @default.
• W2901802145 hasAuthorship W2901802145A5048501863 @default.
• W2901802145 hasAuthorship W2901802145A5064813580 @default.
• W2901802145 hasAuthorship W2901802145A5070412209 @default.
• W2901802145 hasAuthorship W2901802145A5091539607 @default.
• W2901802145 hasBestOaLocation W29018021451 @default.
• W2901802145 hasConcept C104317684 @default.
• W2901802145 hasConcept C121608353 @default.
• W2901802145 hasConcept C149011108 @default.
• W2901802145 hasConcept C190283241 @default.
• W2901802145 hasConcept C207001950 @default.
• W2901802145 hasConcept C2779349466 @default.
• W2901802145 hasConcept C2780210213 @default.
• W2901802145 hasConcept C2780258809 @default.
• W2901802145 hasConcept C2781313199 @default.
• W2901802145 hasConcept C502942594 @default.
• W2901802145 hasConcept C515207424 @default.
• W2901802145 hasConcept C54355233 @default.
• W2901802145 hasConcept C55493867 @default.
• W2901802145 hasConcept C86554907 @default.
• W2901802145 hasConcept C86803240 @default.
• W2901802145 hasConcept C96232424 @default.
• W2901802145 hasConceptScore W2901802145C104317684 @default.
• W2901802145 hasConceptScore W2901802145C121608353 @default.
• W2901802145 hasConceptScore W2901802145C149011108 @default.
• W2901802145 hasConceptScore W2901802145C190283241 @default.
• W2901802145 hasConceptScore W2901802145C207001950 @default.
• W2901802145 hasConceptScore W2901802145C2779349466 @default.
• W2901802145 hasConceptScore W2901802145C2780210213 @default.
• W2901802145 hasConceptScore W2901802145C2780258809 @default.
• W2901802145 hasConceptScore W2901802145C2781313199 @default.
• W2901802145 hasConceptScore W2901802145C502942594 @default.
• W2901802145 hasConceptScore W2901802145C515207424 @default.
• W2901802145 hasConceptScore W2901802145C54355233 @default.
• W2901802145 hasConceptScore W2901802145C55493867 @default.
• W2901802145 hasConceptScore W2901802145C86554907 @default.
• W2901802145 hasConceptScore W2901802145C86803240 @default.
• W2901802145 hasConceptScore W2901802145C96232424 @default.
• W2901802145 hasFunder F4320321001 @default.
• W2901802145 hasIssue "1" @default.

• next